Sampath Anand 4

What Happened

• Sampath Anand, EVP of Operations & Clinical Research at Masimo (MASI), exercised 30,000 stock options at $37.84 per share (cost $1,135,200) on January 28, 2026. The filing also reports open‑market sales of 11,924, 6,560 and 196 shares (total 18,680 shares) for aggregate proceeds of about $2,555,570. The Form 4 shows an additional 30,000‑share derivative entry (reported at $0.00) associated with the exercise/conversion.

Key Details

• Transaction date: 2026-01-28; Form filed 2026-01-30 (timely).
• Exercise: 30,000 shares at $37.84 = $1,135,200.
• Sales (open market):
  • 11,924 shares @ $136.56 = $1,628,341 (weighted avg; actuals ranged $135.94–$136.94).
  • 6,560 shares @ $137.22 = $900,163 (weighted avg; actuals ranged $136.95–$137.89).
  • 196 shares @ $138.09 = $27,066 (weighted avg; actuals ranged $138.07–$138.12).
• Total reported sale proceeds (these three trades): ≈ $2,555,570.
• Shares owned after the transactions: not specified in the provided filing details.
• Notable footnotes:
  • F1: Transactions were executed pursuant to a Rule 10b5‑1 sales plan dated Sept 12, 2025.
  • F2–F4: Reported prices are weighted averages; price ranges given for each sale block.
  • F5: Option was originally granted Feb 29, 2016 and vested over five years.
• Filing timeliness: Report filed within two business days of the transaction date (no late filing indicated).

Context

• This filing shows an option exercise combined with immediate sales under a 10b5‑1 plan — a common way executives convert options to cash while following a pre‑arranged trading plan. The presence of a derivative (M) line and zero‑dollar entry reflects reporting of the option conversion; the separate open‑market sale lines show shares actually sold for cash. These types of transactions are routine and required to be reported, but they do not, by themselves, indicate the insider’s current sentiment about the company.